OMEGA FUNDS

Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Retrieved on: 
Thursday, October 14, 2021
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Scripps Research, The Programme, Degenerative disease, Disease, POC, Partner, Gastrointestinal tract, Therapy, Medication, Pharma, EIF, DVI, Marshall Plan, Precision medicine, Health, Patient, ERP, Biotechnology, Computational biology, Partner (business rank), ABC, BGV, Drug discovery, Alnylam Pharmaceuticals, EUR, Vertex Pharmaceuticals, European Recovery Plan, Liver, Senior, Socially responsible investing, CBO, Department, PFM Group, Eye, Investment, Executive, Central nervous system, Vertex, CFTR, Growth, Atlas, Atlas Venture, EFSI, LFA, Cystic fibrosis, Lists of diseases, Institute of Liver and Biliary Sciences, Company, Omega, Entrepreneurship, United Nations Principles of Medical Ethics, Pharmaceutical industry, Management, Aquaculture, Fine chemical, Rectify Pharmaceuticals, Inc. (“Rectify”), Atlas Venture, Omega Funds, Forbion, Longwood Fund, RECTIFY PHARMACEUTICALS, INC. (“RECTIFY”), ATLAS VENTURE, OMEGA FUNDS, FORBION, LONGWOOD FUND

Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

Key Points: 
  • Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
  • Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
  • We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
  • Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.

Artios raises $153m in Series C financing

Retrieved on: 
Tuesday, July 27, 2021
TCG, Artios Pharma Limited, Omega Funds, TCG X, ARTIOS PHARMA LIMITED, OMEGA FUNDS, TCG X

The oversubscribed financing was co-led by Omega Funds and TCG X.

Key Points: 
  • The oversubscribed financing was co-led by Omega Funds and TCG X.
  • In connection with the close of the Series C financing, Michelle Doig, Partner, Head of Corporate Development, Omega Funds and Chen Yu, Founding Managing Partner, TCG X, will join Artios' Board of Directors.
  • By investing in this financing round we are creating multiple avenues of value creation for our funds' investors."
  • This financing follows an $84 million (65 million) Series B fundraise concluded in August 2018 and yields total capital raised to date from investors and strategic partners of more than US$320 million.